Biglycan therapy


Biglycan therapy project: open for out-licensing or co-development partnership

Summary of invention:

The present invention relates to the use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and anti-ischemic effect, and to the use of them in methods for preventing and treating the atherosclerotic and ischemic (e.g. cardiac) diseases. The invention also relates to screening methods by which biglycan or enhancers of biglycan activity can be identified.

Scientific background:

IP status:

  • Patented technology (primary filing date Jan 2007, WO_2008/084268_A1), granted in EU nad China, in national phase in India.
  • biglycan and glycantherapy are trademarks of Pharmahungary, please see

Planned project duration:

  • 24 months (up to clinical Phase I)
  • If you are interested in our project as an investor or co-development partner, please contact us for further details at

Key publications:

  • Csont T, Görbe A, Bereczki E, Szunyog A, Aypar E, Tóth ME, Varga ZV, Csonka C, Fülöp F, Sántha M, Ferdinandy P. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: role of nitric oxide. J Mol Cell Cardiol. 2010 Apr;48(4):649-52.
  • Csont T, Ferdinandy P. Letter by Csont and Ferdinandy regarding article, “Biglycan is required for adaptive remodeling after myocardial infarction”. Circulation. 2008 Oct 7;118(15):e521.
  • Bereczki E, Gonda S, Csont T, Korpos E, Zvara A, Ferdinandy P, Santha M. Overexpression of biglycan in the heart of transgenic mice: an antibody microarray study. J Proteome Res. 2007 Feb;6(2):854-61.
  • Gáspár R, Pipicz M, Hawchar F, Kovács D, Djirackor L, Görbe A, Varga ZV, Kiricsi M, Petrovski G, Gácser A, Csonka C, Csont T. The cytoprotective effect of biglycan core protein involves toll-like receptor 4 signaling in cardiomyocytes. J Mol Cell Cardiol. 2016 Oct;99:138-150.